Graves' Disease | BHV-1300

No new treatment options for Graves' disease have been approved in over 70 years.

Why Participate?

Graphic illustrating 1 percent of total population
Graphic illustrating 3 percent of Female population

No drug has been approved in over 70 years for a condition that affects 1% of the population—and 3% of women.

Your Decision. Your Potential to Make a Difference.

Joining a clinical trial is a meaningful, personal choice. Here’s an honest look at what participation could offer you — and the broader Graves’ disease community.

Potential Benefits:

Scientific Discovery icon

Access to a New Approach
You may receive an investigational treatment that works differently from anything currently available — one designed to target the underlying cause of your Graves’ disease rather than just managing symptoms.

Receive Comprehensive Care icon

Expert Medical Care
Study participants receive close attention from a dedicated medical team throughout the study. This includes regular lab tests, health assessments and monitoring that may go beyond what is typically available in routine care.

No Cost For Study Participants icon

No Cost for Study Treatment
The investigational study drug, study-related procedures and clinic visits are provided at no cost to participants. You will not pay for BHV-1300 or the study-related tests.

Make A Difference icon

Help Future Patients
By participating, you contribute to research that could shape how Graves’ disease is treated for the next generation. Your involvement helps answer whether a new approach can finally address the root cause of this disease.

Self Administration At Home icon

Self Administration at Home
After your first supervised dose, you can administer BHV-1300 yourself at home using a simple auto-injector — minimizing disruption to your daily routine throughout the 26-week treatment period.

Ready to Get Involved icon

Ready to Get Involved?
See if you qualify and take the first step toward making a meaningful impact on the lives of those living with Graves’ disease. Together, we can drive progress in research and bring new hope to patients everywhere.